Current treatments for MCI and Alzheimer disease and related dementias include 3 Food and Drug Administration (FDA)–approved cholinesterase inhibitors [100], which increase cholinergic signaling by slowing the breakdown of acetylcholine in and around the synaptic cleft. Here, BCHE is linked to dementia.